



STEROIDAL ATHLETE BIOLOGICAL PASSPORT WORKING GROUP

Terms of Reference

The WADA Steroidal Athlete Biological Passport Working Group [Steroidal ABP WG] is a specific Working Group¹ created by WADA Management.

These Terms of Reference are approved by the WADA Director General, following consultation with the responsible Director in charge of the Group and the Chair of the WADA Health, Medical and Research Committee.

Purpose

To be responsible for providing expert advice, recommendations and guidance to WADA Management with regards to the steroidal module of the Athlete Biological Passport (ABP) program.

Objectives/Key Activities

- 1) To assist WADA in the development and refinement of the ABP, and more specifically the steroidal module, including updating the ABP Operating Guidelines and related Standards/Technical Documents.
- 2) To examine the performance of existing markers and assist in the identification and understanding of potential sources of variance and confounding factors in order to provide recommendations for the improved effectiveness and efficiency of the steroid module.
- 3) Provide guidance for research for the development of the ABP, in particular through the development of new biomarkers.
- 4) To monitor and examine trends in the use of the ABP by Anti-Doping Organizations (including, but not limited to, improving target testing, additional analyses and establishing analytical and non-analytical anti-doping rule violations) and to identify potential threats/risks to the ABP.
- 5) To assist WADA in the event of a review and/or appeal of an ABP case, upon request.

¹ WGs are created on an as-needed basis only, and generally with a defined mandate requiring deliverables within a set timeframe. Where the expected deliverables are not met, an extension of mandate is possible, however it is not expected that WGs continue indefinitely. If it is considered that their work should be ongoing in nature, whether WG should be elevated to an Expert Advisory Group would need to be determined.

Reporting Structure

The Steroidal ABP WG reports to WADA Management and provides an annual report to the *WADA Health, Medical and Research Committee*.

Membership/Composition

The composition of the Steroidal ABP WG shall not exceed a maximum of 8-10 members however an exception may be applied if deemed necessary.

The WADA Director General, following consultation with the responsible Director in charge of Steroidal ABP WG and the Chair of the WADA Health, Medical and Research Committee will appoint members to the Steroidal ABP WG.

Members are selected on the basis of their relevant background and experience (e.g. expertise in the use of the ABP, the fields of laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology, as they apply to steroid doping).

The Members of the Steroidal ABP WG are as follows:

1. Prof. Peter Van Eenoo (Belgium) - CHAIR
2. Dr. Hans Geyer (Germany)
3. Prof. Martial Saugy (Switzerland)
4. Prof. Eberhard Nieschlag (Germany)
5. Prof. Christiane Ayotte (Canada)
6. Prof. Yves Le Bouc (France)
7. Dr. Matt Fedoruk (USA)

If required, additional experts may be called upon on an ad-hoc basis for their contributions.

Chair/Rapporteur

The Steroidal ABP WG Chair² is selected based on his/her proven record and expertise in the use of the ABP, the fields of laboratory steroid analysis, steroid doping and metabolism, and/or clinical endocrinology, as they apply to steroid doping.

He/she shall act as the official reporter who is responsible for ensuring appropriate coordination with WADA Management, delivering the annual report to the Chair of the WADA Health, Medical and Research Committee and for providing accurate and timely information on all relevant issues.

WADA Liaison

The WADA Science and Medical Department, and in particular the Deputy Director ABP, will serve as the primary liaison between WADA and the Steroidal ABP WG.

The Deputy Director ABP will be an observer³ to the Steroidal ABP WG in the sense that he/she contributes to and brings expertise to support the work of the Steroidal ABP WG but does not have a voting position. Additional WADA Science and Medical Department staff may also

² There are occasions where WADA staff may chair a WG, e.g. when an external chair is not deemed to be practical.

³ Unless they are appointed as the Chair of the WG.

participate in Steroidal ABP WG meetings as WADA experts on particular subject matters and to provide general support to the group where required.

Meetings and Working Norms

The Steroidal ABP WG will generally meet yearly in person for a two-day meeting, or virtually via video or teleconference (as determined by WADA) as many times as is necessary to complete its mandate.

The Steroidal ABP WG normally operates on the basis of consensus and maintains as informal a manner as is possible or appropriate for the conduct of business. Consensus will be sought whenever possible. In the event of divergence of opinion or disagreement concerning recommendations, the absolute majority (determined by vote by hand) will rule. In the event of a tie, the Chair has the casting vote. There is presently no formal practice concerning a quorum. The Chair has the responsibility to determine if a quorum is present. Meeting notes will record any dissenting opinion on request.

The Chair may limit discussion of resurfacing issues by referring to previous recommendations or conclusions of previous discussions.

Meeting notes of the Steroidal ABP WG meetings, reports and correspondence relative to the group's work shall be open, recorded and retained at the WADA Headquarters.

Conflict of Interest

Steroidal ABP WG members will be bound by the Conflict of Interest policy adopted by the WADA Foundation Board in November 2019⁴, and will be required to annually complete and sign a Statement of Absence of Conflict of Interest in accordance with the policy.

Confidentiality

All group members are required to sign a Confidentiality Agreement upon appointment (and again at the start of each year if their appointment is renewed). This ensures all members reflect on the confidential nature of their WADA work and confirm their adherence to such confidentiality rules. Signing this document each year is a new process as of 2020 (as a result of the governance changes mentioned above); previously members were only required to sign once.

Communications and Media

All Steroidal ABP WG members must read and comply with WADA's Media Relations policy. If a member should receive a request for an interview in relation to their role in WADA or WADA's work they should first consult with the WADA Media Relations Senior Manager or (if absent), with the WADA Communications Director.

⁴ WADA's Foundation Board approved a set of governance reforms in November 2018 at its meeting in Baku, Azerbaijan. In 2019, WADA's Statutes were modified to reflect these reforms, and a new set of bylaws and operational regulations were created to supplement the formal Statutes. They were approved by WADA's Foundation Board in November 2019 in Katowice, Poland.

Budget and Financial Support

WADA shall provide the necessary administrative and operational resources for meetings. WADA will meet all travel and accommodation costs, as well as most meals onsite. A daily indemnity is provided to cover incidental costs during travel to and from the meeting.

Where meetings are held virtually and meet certain rules such as a minimum duration, a daily indemnity for virtual attendance is disbursed.

It is acknowledged that some experts go above and beyond, including providing extensive advice throughout the year, outside of annual meetings. WADA offers a further daily indemnity to experts for such work carried out. The specific indemnity details are outlined in the "Overview of WADA Working Groups" document.

Effective Date

The Steroidal ABP WG originally came into effect in 2012. The mandate remains the same as initially drafted and/or approved. The ToR have however been updated to reflect practical changes to the way in which WADA manages its Working Groups which were approved in November 2020 and come into effect on 1 January 2021.

These ToR are published on the WADA website.